대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	Efficacy and Safety of Dapagliflozin in Diabetic Kidney Transplant Recipients
저자	Sherzod Abdullaev
출판정보	2024; 2024(1):
키워드
초록	Objectives: SGLT2 inhibitors are a class of prescription medicines that are FDA-approved for use with diet and exercise to lower blood sugar in adults with type 2 diabetes. However, there are no recommendations regarding its use in diabetic kidney transplant recipients (KTR). The aim of our study was to evaluate the efficacy and safety of dapagliflozin in diabetic KTR. Methods: Patients were randomized to dapagliflozin 10 mg once daily (diabetic KTR using SGLT2i) and controls (diabetic KTR not using SGLT2i) were matched for recipient age, gender, year of transplant, and donor type. Results: There were 32 patients in dapagliflozin groups and 35 controls. The mean follow-up period in SGLT2i and controls was 22.9 and 23.1 months, respectively. Both groups had similar baseline graft function and HbA1c. Compared to controls, dapagliflozin group had a statistically significant reduction of BMI (-1.2 vs. +0.22; P<0.001). There was also a trend for better graft function and diabetes control, but it did not reach statistical significance. Both groups had similar adverse events such as AKI, urinary tract infection, cardiovascular and cerebrovascular complications. Conclusions: SGLT2i use in diabetic KTR was associated with a significant reduction in BMI and a trend for better kidney function and diabetes control. Longer prospective randomized controlled trials are needed to confirm their safety and efficacy outcomes in KTR.
원문(PDF)	PDF 원문보기

목록

위로가기